Deskripsi
Enrollment and randomization flow for the double-blind, placebo-controlled trial evaluating Bacillus coagulans MTCC 5856 in diarrhea-predominant IBS patients. The diagram outlines how 36 participants were screened, allocated to active or placebo groups, and followed through four study visits.
Figure 1
FlowchartSource Paper
Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled …Cite This Figure
![Figure 1: Enrollment and randomization flow for the double-blind, placebo-controlled trial evaluating Bacillus coagulans MTCC 5856 in diarrhea-predominant IBS patients. The diagram outlines how 36 participants were screened, allocated to active or placebo groups, and followed through four study visits.]() > Source: Muhammed Majeed et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predo." *Nutrition journal*, 2016. PMID: [26922379](https://pubmed.ncbi.nlm.nih.gov/26922379/)
<figure> <img src="" alt="Enrollment and randomization flow for the double-blind, placebo-controlled trial evaluating Bacillus coagulans MTCC 5856 in diarrhea-predominant IBS patients. The diagram outlines how 36 participants were screened, allocated to active or placebo groups, and followed through four study visits." /> <figcaption>Figure 1. Enrollment and randomization flow for the double-blind, placebo-controlled trial evaluating Bacillus coagulans MTCC 5856 in diarrhea-predominant IBS patients. The diagram outlines how 36 participants were screened, allocated to active or placebo groups, and followed through four study visits.<br> Source: Muhammed Majeed et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predo." <em>Nutrition journal</em>, 2016. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26922379/">26922379</a></figcaption> </figure>